Choose Medical News By Speciality
Some feed pages can be slow to load
Some feed pages can be slow to load
Management approach to these findings includes axillary ultrasound if clinical concern persists six weeks after final dose of vaccine
Lowest mortality seen with two servings of fruit and three servings of vegetables; no additional risk reduction seen with higher intake
Screening rates improved in patients due for testing at a community health center predominantly serving people of color
Use of thromboprophylaxis not recommended for ambulatory patients at low risk for VTE who are receiving chemotherapy
Lorlatinib, a potent, brain-penetrant, third-generation ALK tyrosine kinase inhibitor (TKI), has substantial activity against ALK-positive non-small-cell lung cancer (NSCLC). This study assessed the overall, intracranial, and extracranial efficacy of lorlatinib [...]
To determine the incidence of serious chronic health conditions among survivors of pediatric Hodgkin lymphoma (HL), compare by era of therapy and by selected cancer therapies, and provide estimates of [...]
We predicted cancer mortality statistics for 2021 for the European Union (EU) and its five most populous countries plus the UK. We also focused on pancreatic cancer and female lung [...]
To test the efficacy of screening by clinical breast examination in downstaging breast cancer at diagnosis and in reducing mortality from the disease, when compared with no screening.Prospective, cluster randomised [...]
Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Phase II studies [...]
Surveillance is now strongly recommended for survivors treated with ≥10 Gy chest radiation — a change from ≥20 Gy.
The American Society of Hematology presents guidelines for the management of cancer-associated thrombosis.
The combination of lenvatinib plus pembrolizumab showed an overall survival benefit over sunitinib in this phase 3 trial.
Meta-analysis indicates that having 1 to 2 small adenomas imparts risk similar to having no adenomas.
All the major study endpoints favored enfortumab vedotin over chemotherapy in this phase 3 trial.
Single Use Tubing Sets Brochure